Beat
The top-line beat was broad, while US electrophysiology began to normalize from exceptional levels.
[AS-EXP-029]Boston Scientific
Q3 2025: WATCHMAN acceleration and an above-Street fourth-quarter guide provided relief, but a narrower electrophysiology surprise capped the move.
ResultBeatGuidanceMixed / newly framedEnvironmentmixed
Investment snapshot
What happened and why it mattered
Mixed / newly framed
The fourth-quarter organic-sales guide exceeded consensus and preserved the annual growth narrative.
[AS-EXP-029]No clear inflection
The fourth-quarter organic-sales guide exceeded consensus and preserved the annual growth narrative.
[AS-EXP-029]Qualitative
The shares rose modestly as WATCHMAN improved, then investors refocused on the electrophysiology deceleration.
[AS-ME-085]Results versus expectations
The print and the three most important read-throughs
The top-line beat was broad, while US electrophysiology began to normalize from exceptional levels.
- 1
The top-line beat was broad, while US electrophysiology began to normalize from exceptional levels.
Guidance bridge
GuidanceMixed / newly framedLatest outlook and KPI implications
The fourth-quarter organic-sales guide exceeded consensus and preserved the annual growth narrative.
| Metric | Prior | Latest | Consensus | Delta | Status | Reason / implication |
|---|---|---|---|---|---|---|
| FY25 organic sales growth | 14–15% | ~15.5% | ~14.6% | +100bps at midpoint | Updated | Sustained above-market growth |
| FY25 reported sales growth | 18–19% | ~20% | ~18.7% | +~150bps at midpoint (extra FX) | Updated | Higher FX tailwind (~100bps) + performance |
| FY25 operational growth | 17.5–18.5% | ~19% | n/a | Higher | Raised | Broad-based execution |
| FY25 adjusted EPS | $2.95–$2.99 | $3.02–$3.04 | $2.98 | +$0.06 at midpoint (+~2%) | Updated | Strong drop-through on revenue/margin |
| FY25 adjusted gross margin | Roughly in line with 2024 | Slightly improve vs 2024 | n/a | Upgraded | Updated | Favorable mix from EP/WATCHMAN/AGENT |
| FY25 adjusted operating margin expansion | +75–100bps | ~100bps (high end) | n/a | Raised to high end | Raised | YTD margin performance |
Management signal — paraphrased
The fourth-quarter organic-sales guide exceeded consensus and preserved the annual growth narrative.
Implied cadence
The fourth-quarter organic-sales guide exceeded consensus and preserved the annual growth narrative.
Stock reaction
Why the shares moved
The shares rose modestly as WATCHMAN improved, then investors refocused on the electrophysiology deceleration.
- The shares rose modestly as WATCHMAN improved, then investors refocused on the electrophysiology deceleration.
Did the reaction persist?
[AS-ME-085]Not independently calculated in the compact record.
Adjusted-close reaction
Independent return windows were not embedded in this compact record. The reaction assessment is qualitative.
Source-reported qualitative reaction; no independent price series embeddedMarket environment delta
EnvironmentmixedWhat management said about the operating backdrop
WATCHMAN acceleration and an above-Street fourth-quarter guide provided relief, but a narrower electrophysiology surprise capped the move.
- Customer demandImproving
No signals of procedures pulled forward on ACA/Medicare-cut fears; ~25% concomitant WATCHMAN exiting 2025
OutlookConcomitant potential to double by 2028KPI implicationWATCHMAN organic +34.6%Management interpretation · High confidence · [111] - Volumes / proceduresImproving
FARAPULSE >500,000 patients treated; 1 in 3 US accounts using FARAWAVE NAV + OPAL
OutlookUS FARAPULSE double-digit growth continuingKPI implicationEP $865M; mapping pull-throughDisclosed fact · High confidence · [112] - Regional / end-marketMixed
US +27%; EMEA −2% on ACURATE + ERP (HSD ex-both); APAC +16.9%; China mid-teens
OutlookEMEA recovery as transient drags abateKPI implicationUS and APAC broad-based strengthDisclosed fact · High confidence · [153]
- Channel / inventoryWorsening (transient)
New ~$30M Kerkrade ERP backorder, weighted to MedSurg/PI; less impact on EP/WATCHMAN
OutlookExpected to bleed down to acceptable levels by year-endKPI implication~70bps drag to Q3 growth (DB estimate)Disclosed fact · High confidence · [113] - Supply availabilityImproving
Same ERP-driven European supply disruption "certainly looks better now than 60 days ago"
OutlookResidual 4Q impact abating into year-endKPI implicationBackorder recoveryManagement interpretation · Medium confidence · [114] - Input costs / margins / tariffsImproving
~$100M tariff unchanged; GM now to "slightly improve versus 2024" on EP/WATCHMAN mix
OutlookAdjusted OM to expand ~100bps (high end of prior 75-100bps)KPI implicationGM 71.0%; OM 28.0%Disclosed fact · High confidence · [115]
- Competition (PFA/EP)Stable
Moved from #4 to clear #2 in EP; expects to retain PFA leadership, exit 2025 at ~50% PFA penetration to ~80% by 2028
OutlookAbove ~15% market growth through 2028 despite new entrantsKPI implicationEP organic +62.8%; share retention keyManagement interpretation · Medium confidence · [110] - Pricing (China VBP)Stable
China grew mid-teens "despite the substantial VBP" in peripheral, offset by ICTx and EP
OutlookMid-teens China CAGR sustained through LRPKPI implicationPI organic +6.3%, dragged by arterial VBPDisclosed fact · Medium confidence · AS-ME-085
Evidence and confidence
Source map
No material gap recorded.
AlphaSense synthesis
Open source ↗Official company source
Open source ↗AlphaSense market-environment synthesis
Open source ↗